Citations

Clear

400 citation(s) found for "Berry, DA".

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Albain, Kathy S. , Yau, Christina , Petricoin, Emanuel F. , Wolf, Denise M. , Lang, Julie E. , Chien, A. Jo , Haddad, Tufia C. , Forero-Torres, Andres , Wallace, Anne M. , Kaplan, Henry G. , Euhus, David , Nanda, Rita , Clark, Amy S. , Godellas, Constantine , Tripathy, Debu , Lu, Janice , Yung, Rachel L. , Wulfkuhle, Julia , Krings, Gregor , Chen, Yunn‐Yi , Potter, David A. , Stringer-Reasor, Erica , Blair, Sarah L. , Asare, Smita , Wilson, Amy , Hirst, Gillian L. , Singhrao, Ruby , Buxton, Meredith , Clennell, Julia L. , Sanil, Ashish, Matthews, Jeffrey B. , Melisko, Michelle , Perlmutter, Jane , Symmans, W. Fraser , Veer, Laura J. van’t , Yee, Douglas , Berry, Donald A. , Haddad, Tufia C , Kaplan, Henry , Pusztai, Lajos , Euhus, David , Nanda, Rita , Elias, Anthony D , Clark, Amy S , Godellas, Constantine , Boughey, JC , Isaacs, Claudine , Tripathy, Debasish , Lu, Janice , Yung, Rachel L , Gallagher, Rosa I , Wulfkuhle, Julia D , Brown-Swigart, Lamorna , Krings, Gregor , Chen, Yunn Yi , Potter, David A , Stringer-Reasor, Erica , Blair, Sarah L , Asare, Smita M , Wilson, Amy , Hirst, Gillian L , Singhrao, Ruby , Buxton, Meredith , Clennell, Julia L , Berry, Scott , Asare, Adam L , Matthews, Jeffrey B , DeMichele, Angela , Hylton, Nola M. , Melisko, Michelle , Perlmutter, Jane , Rugo, Hope S , Symmans, W Fraser , Yee, Douglas , Berry, Donald , Esserman, Laura J , Pusztai, Lajos , Elias, Anthony , Boughey, Judy C. , Isaacs, Claudine , Gallagher, Rosa I. , Swigart, Lamorna Brown , Asare, Adam L. , DeMichele, Angela , Rugo, Hope S. , Esserman, Laura J.

Mayo Clinic

Clinical Cancer Research | December 18, 2023 | Volume: 30 | Issue: 4 | Pages: 729-740

10.1158/1078-0432.ccr-22-2256 | PMID 38109213 Get It

Abstract Purpose: The neutralizing peptibody trebananib prevents angiopoietin-1 and angiopoietin-2 from binding with Tie2 receptors, inhibiting angiogenesis and proliferation. Trebananib was combined with paclitaxel±trastuzumab in the I-SPY2 breast cancer trial. Patients and Methods: I-SPY2, a phase II neoadjuvant trial, adaptively randomizes patients with high-risk, early-stage breast cancer to one of several experimental therapies or control based on receptor subtypes as defined by hormone receptor (HR) and HER2 status and MammaPrint risk (MP1, MP2). The primary endpoint is pathologic complete response (pCR). A therapy “graduates” if/when it achieves 85% Bayesian probability of success in a phase III trial within a given subtype. Patients received weekly paclitaxel (plus trastuzumab if HER2-positive) without (control) or with weekly intravenous trebananib, followed by doxorubicin/cyclophosphamide and surgery. Pathway-specific biomarkers were assessed for response prediction. Results: There were 134 participants randomized to trebananib and 133 to control. Although trebananib did not graduate in any signature [phase III probabilities: Hazard ratio (HR)-negative (78%), HR-negative/HER2-positive (74%), HR-negative/HER2-negative (77%), and MP2 (79%)], it demonstrated high probability of superior pCR rates over control (92%–99%) among these subtypes. Trebananib improved 3-year event-free survival (HR 0.67), with no significant increase in adverse events. Activation levels of the Tie2 receptor and downstream signaling partners predicted trebananib response in HER2-positive disease; high expression of a CD8 T-cell gene signature predicted response in HR-negative/HER2-negative disease. Conclusions: The angiopoietin (Ang)/Tie2 axis inhibitor trebananib combined with standard neoadjuvant therapy increased estimated pCR rates across HR-negative and MP2 subtypes, with probabilities of superiority >90%. Further study of Ang/Tie2 receptor axis inhibitors in validated, biomarker-predicted sensitive subtypes is warranted.
NurOwn® Phase 2 ALS Trial: ALSFRS-R Improvement is Reflected in Subscale Domains (S38.002)
Kern, R. , Windebank, Anthony J. , Owegi, Margaret, Lebovits, Chaim, Gothelf, Yaël, Brown, Robert H. , Cudkowicz, Merit , Berry, James D. , Staff, Nathan P.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s38.002 Get It

MODULATION OF CSF miRNAs IN ALS PHASE 2 STUDY PARTICIPANTS TREATED WITH MSC-NTF CELLS (NUROWN®) (S25.005)
Aricha, Revital , Kaspi, Haggai , Windebank, Anthony J. , Owegi, Margaret, Levy, Yossef S., Lebovits, Chaim, Brown, Robert H. , Gothelf, Yaël, Kern, R. , Cudkowicz, Merit , Berry, James D. , Staff, Nathan P.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s25.005 Get It

CSF biomarkers evaluated by principal component analysis in a NurOwn Phase 3 clinical trial (P1-1.Virtual)
Brown, Robert H. , Aricha, Revital , Kern, R. , Windebank, Anthony J. , Goyal, Namita , Katz, Jonathan, Burford, Matthew, Levy, Yossef S., Lebovits, Chaim, Gothelf, Yaël, Boulanger, Bruno , Mehra, Munish, Lindborg, Stacy , Berry, James D. , Cudkowicz, Merit , Staff, Nathan P. , Miller, Robert G. , Mehra, Munish

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.2796 Get It

A three-dimensional computed tomography study of the palmar ulnar corner fragment in distal radial fractures
Hubbard, James C. , Chauhan, Aakash , Casstevens, Chris, Abrams, Reid A. , Abrams, Reid A , Berry, David B. , Shin, Alexander Y.

Mayo Clinic

Journal of Hand Surgery (European Volume) | November 17, 2023 | Volume: 49 | Issue: 3 | Pages: 300-309

10.1177/17531934231211570 | PMID 37974338 Get It

Fixing palmar ulnar corner fragments of distal radial fractures can be challenging. We described the palmar ulnar corner fragment morphology in a retrospective cohort study of 40 patients who underwent preoperative wrist computed tomography scans. Palmar ulnar corner fractures were categorized based on articular cross-sectional area, sagittal angulation relative to the radius long axis, palmar cortical length, radioulnar width and associated palmar radiocarpal subluxation. Three types emerged: type 1 fragments involved 37% (SD 10) of the radiocarpal articular surface and were extended in the sagittal plane; type 2 fragments involved 28% (SD 10) of the articular surface and had a long palmar cortex, of which 57% had palmar carpal subluxation; and type 3 fragments involved 13% (SD 2) of the articular surface, had a short palmar cortex and all had palmar carpal subluxation. Understanding palmar ulnar corner fragment morphology may guide optimal reduction and fixation strategy and prevent palmar radiocarpal subluxation, especially in type 3 fractures. Level of evidence IV
EXTH-37. FUNCTIONAL GENOMICS IDENTIFIES THERAPEUTIC VULNERABILITIES OF GLIOMA SUBTYPES AND YAP/TAZ-ENRICHED TUMORS
Lin, Wan‐Hsin , Kosari, Farhad , Smadbeck, James B. , Barrett, Michael T. , Feathers, Ryan W. , Penheiter, Alan R. , Lynch, Jamie, Sadeghian, Dorsay, Maruthi, Vijaya Kadam, Johnson, Sarah H. , Karagouga, Giannoula, Harris, Faye R. , Berry, T. Dennis, McCune, Alexa, Kinsella, Lindsey, Yang, Lin , Emanuel, Angela, Salvatori, Rebecca , Klein, Janet Schaefer, Ida, Cristine, Jentoft, Mark E. , Sherman, Wendy, Porter, Alyx B. , Rosenfeld, Steven S. , Kizilbash, Sani H. , Jaeckle, Kurt A. , Mrugała, Maciej M. , Quiñones‐Hinojosa, Alfredo , Cheville, John C. , Vasmatzis, George , Anastasiadis, Panos Z. , Kizilbash, Sani H , Sotiriou, Sotiris , Berry, Taylor, Murphy, Stephen J. , Moniz‐Garcia, Diogo , Ensign, Shannon P. Fortin , Salomao, Marcela , Mansfield, Aaron S. , Borad, Mitesh J. , Bendok, Bernard R. , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v232-v232

10.1093/neuonc/noad179.0890 Get It

Abstract Sequencing efforts have identified key oncogenic drivers and transcriptomic subtypes of high-grade gliomas (HGGs), but this knowledge has not resulted in individualized therapy or improved patient outcomes. Here, we used a functional genomics approach combining integrated genomic/transcriptomic analyses with patient-derived 3D micro-cancers (mCancers) to rapidly identify individualized therapeutic vulnerabilities and determine predictive response biomarkers. 30 primary/recurrent HGGs, including 20 glioblastomas, 5 astrocytomas, and 5 oligodendrogliomas, were included for drug testing. mCancers recapitulated the structural and molecular alterations, cellularity, and heterogeneity, of parental patient tumors. A total of 119 single-agent drugs and 183 drug combinations were tested, while a pre-selected drug panel comprising 25 glioma-relevant treatment strategies was tested across all cases. In general, mCancer efficacy corresponded well to historical responses to previously tested agents (EGFR, HDAC inhibitors, etc.). Combined, strong efficacy (i.e. >70% growth inhibition at Cmax) of single treatments targeting deregulated receptor tyrosine kinase (RTK), p53/apoptosis, cell cycle, DNA damage repair, IDH, or telomere maintainance pathways, was observed in 14 out of 30 cases. Surprisingly, transcriptional signatures, but not specific genetic alterations, were found to stratify drug responses. For example, mCancers enriched for the most aggressive mesenchymal (MES) and glycolytic/plurimetabolic (GPM) transcriptional subtypes exhibited stronger response to the BET inhibitor JQ1 (and other clinical BET inhibitors) and the DNA-PKcs/mTOR dual inhibitor CC-115. This therapeutic vulnerability was associated with enrichment of YAP/TAZ signaling, and the glioblastoma stem cell G-STEM signature. Notably, individual combination strategies were effective across tumors, with strong responses ranging from 38% to 77% of all tumors tested. Overall, this study underscores the value of functional genomics in identifying novel vulnerabilities of HGGs and associated response biomarkers. It also highlights the need for further clinical validation of several novel therapies and especially drug combination strategies with strong efficacy in the ex vivo setting.
S507 Esophageal Expert Development of a Disease-Specific Question Prompt List for Adults With Eosinophilic Esophagitis: A Modified Delphi Study
Achalu, Sudharshan, Berry, Rani , Bhargava, Meera , Chang, Joy W. , Fernandez‐Becker, Nielsen , Hirano, Ikuo , Horsley‐Silva, Jennifer L. , Leiman, David A. , Lynch, Kristle L. , Kamal, A. N. , Bredenoord, Albert J. , Dellon, Evan S. , Falk, Gary W. , Peterson, Kathryn A. , Kamal, Afrin N.

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S370-S370

10.14309/01.ajg.0000951668.71231.a7 Get It

Bilateral Laser Interstitial Thermal Therapy for Butterfly Gliomas Compared With Needle Biopsy: A Preliminary Survival Study
Daggubati, Lekhaj , Merenzon, Martín A. , Bhatia, Shovan , Berry, Katherine , Chandar, Jay , Komotar, Ricardo J., Daggubati, Lekhaj C , Ramos‐Fresnedo, Andres , Morell, Alexis Andres , Shah, Ashish Harish , Ivan, Michael E

Mayo Clinic

Operative Neurosurgery | October 16, 2023 | Volume: 25 | Issue: 5 | Pages: 435-440

10.1227/ons.0000000000000850 | PMID 37846139 Get It

BACKGROUND AND OBJECTIVES: Bilateral/butterfly glioblastoma (bGBM) has a poor prognosis. Resection of these tumors is limited due to severe comorbidities that arise from surgical procedures. Laser interstitial thermal therapy (LITT) offers a minimally invasive cytoreductive therapy for deep-seated tumors such as bGBM. The objective of this study was to evaluate the safety of bilateral LITT in patients with bGBM. METHODS: Medical records of all consecutive patients diagnosed with bGBM by a single surgeon at a single institution from January 2014 to August 2022 were reviewed. Clinical, safety, and radiographic volumetric data were obtained. In addition, an exploratory analysis of survival was performed. RESULTS: A total of 25 patients were included; 14 underwent biopsy only, and 11 underwent biopsy + LITT (7 underwent bilateral and 4 underwent unilateral LITT). No (0%) intraoperative or postoperative complications were recorded in the treatment group. Tumor volume negatively correlated with extent of treatment (r 2 = 0.44, P = .027). The median progression-free survival was 2.8 months in the biopsy-only group and 5.5 months in the biopsy + LITT group ( P = .026). The median overall survival was 4.3 months in the biopsy-only group and 10.3 months in the biopsy + LITT group ( P = .035). CONCLUSION: Bilateral LITT for bGBM can be safely performed and shows early improvement of the progression-free survival and long-term survival outcomes of these patients.
Stem-like CD4 + T cells in perivascular tertiary lymphoid structures sustain autoimmune vasculitis
Sato, Yuki , Jain, Abhinav , Ohtsuki, Shozo , Okuyama, Hirohisa , Sturmlechner, Ines , Takashima, Yoshinori , Le, Kevin , Bois, Melanie C. , Berry, Gerald J. , Goronzy, Jörg J. , Weyand, Cornelia M. , Le, Kevin-Phu C , Goronzy, Jorg , Weyand, Cornelia , Jain, Abhinav , Berry, Gerald J , Sturmlechner, Ines , Warrington, Kenneth J.

Mayo Clinic

Science Translational Medicine | September 6, 2023 | Volume: 15 | Issue: 712 | Pages: No page available

10.1126/scitranslmed.adh0380 | PMID 37672564 Get It

Autoimmune vasculitis of the medium and large elastic arteries can cause blindness, stroke, aortic arch syndrome, and aortic aneurysm. The disease is often refractory to immunosuppressive therapy and progresses over decades as smoldering aortitis. How the granulomatous infiltrates in the vessel wall are maintained and how tissue-infiltrating T cells and macrophages are replenished are unknown. Single-cell and whole-tissue transcriptomic studies of immune cell populations in vasculitic arteries identified a CD4 + T cell population with stem cell–like features. CD4 + T cells supplying the tissue-infiltrating and tissue-damaging effector T cells survived in tertiary lymphoid structures around adventitial vasa vasora, expressed the transcription factor T cell factor 1 (TCF1), had high proliferative potential, and gave rise to two effector populations, Eomesodermin (EOMES) + cytotoxic T cells and B cell lymphoma 6 (BCL6) + T follicular helper-like cells. TCF1 hi CD4 + T cells expressing the interleukin 7 receptor (IL-7R) sustained vasculitis in serial transplantation experiments. Thus, TCF1 hi CD4 + T cells function as disease stem cells and promote chronicity and autonomy of autoimmune tissue inflammation. Remission-inducing therapies will require targeting stem-like CD4 + T cells instead of only effector T cells.
Whole Blood Metal Levels in the Setting of an Oncologic Endoprosthesis: Is There Cause for Concern?
Houdek, Matthew T. , Couch, Cory G., Rose, Peter S. , Lewallen, David G. , Berry, Daniel J. , Kremers, Hilal Maradit , Houdek, Matthew T , Berry, Daniel J , Wyles, Cody C. , Taunton, Michael J.

Mayo Clinic

Clinical Orthopaedics & Related Research | August 21, 2023 | Volume: 482 | Issue: 2 | Pages: 352-358

10.1097/corr.0000000000002805 | PMID 37603308 Get It

Abstract Background Massive modular endoprostheses have become a primary means of reconstruction after oncologic resection of a lower extremity tumor. These implants are commonly made with cobalt-chromium alloys that can undergo wear and corrosion, releasing cobalt and chromium ions into the surrounding tissue and blood. However, there are few studies about the blood metal levels in these patients. Question/purpose What is the whole blood cobalt and chromium ion level in patients with massive modular endoprostheses? Methods We performed a cross-sectional study of our total joints registry to identify patients with a history of an endoprosthetic reconstruction performed at our institution. Patients who were alive at the time of our review in addition to those undergoing an endoprosthetic reconstruction after an oncologic resection were included. Whole blood samples were obtained from 27 (14 male and 13 female) patients with a history of a lower extremity oncologic endoprosthesis. The median time from surgery to blood collection was 8 years (range 6 months to 32 years). Blood samples were collected and stored in metal-free ethylenediaminetetraacetic acid tubes. Samples were analyzed on an inductively coupled plasma mass spectrometer in an International Organization for Standardization seven-class clean room using polytetrafluoroethylene-coated instruments to reduce the risk of metal contamination. The analytical measuring range was 1 to 200 ng/mL for chromium and cobalt. Cobalt and chromium levels were considered elevated when the blood level was ≥ 1 ppb. Results Cobalt levels were elevated in 59% (16 of 27) of patients, and chromium levels were elevated in 26% (seven of 27). In patients with elevated metal ion values, 15 of 17 patients had a reconstruction using a Stryker/Howmedica Global Modular Replacement System implant. Conclusion Blood metal levels were elevated in patients who received reconstructions using modular oncology endoprostheses Future work is needed to establish appropriate follow-up routines and determine whether and when systemic complications occur because of elevated metal levels and how to potentially address these elevated levels when complications occur. Prospective and retrospective collaboration between multiple centers and specialty societies will be necessary to address these unknown questions in this potentially vulnerable patient group. Level of Evidence Level IV, therapeutic study.